Email this article Role of monoclonal antibodies in therapy of lymphoproliferative disorders
- Authors: Von Stackelberg A..1, Romanova K.I.2
-
Affiliations:
- Charité-Universitaetsmedizin Berlin
- Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России
- Issue: Vol 14, No 2 (2015)
- Pages: 20-37
- Section: ЛИМФОМЫ
- Submitted: 19.09.2018
- Published: 19.05.2015
- URL: https://hemoncim.com/jour/article/view/100
- DOI: https://doi.org/10.24287/1726-1708-2015-14-2-20-37
- ID: 100
Cite item
Full Text
Abstract
The development of monoclonal antibodies (mAbs) for the treatment of hematological malignancies is in the focus of modern research. Several antibodies (Abs) effective in the treatment of acute lymphoblastic leukemia (ALL) in children are used at present. Nonconjugated humanized Abs are well tolerated and can be combined with chemotherapy, while immunoconjugats (with a second molecule - toxin, radioisotope, or label), delivering toxic compounds directly to the target cells, are fraught with serious side effects. Antigens with high selective expression on pathological cells are the ideal targets for Abs, their clinical trials (phases I/II and III) in children with ALL are now in progress. Antigens with stable expression on cell membrane (CD19, CD52) serve as substrates for bi-specific T-cell engagers (BiTEs) or for nonconjugated Abs realizing their mechanism of action through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Antigens subjected to rapid internalization (CD22, CD5, CD7) are suitable targets for immunoconjugates delivering toxic substances directly to target cells by specific binding. Effective compounds, corresponding to various antigens expressed in only certain ALL subgroups (CD20, CD33, CD2, CD3, CD4), can be used for therapy of patients with refractory leukemias. The mechanism of antileukemic activity of mAbs is quite different in comparison with chemotherapy; this approach is expected to modify significantly the therapeutic strategy in childhood ALL.
About the authors
A. . Von Stackelberg
Charité-Universitaetsmedizin Berlin
Author for correspondence.
Email: arend.stackelberg@charite.de
Russian Federation
K. I. Romanova
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России
Email: romanovaksen@gmail.com
Russian Federation
References
Supplementary files
